Lipid mediators involved in the oxidative stress and antioxidant defence of human lung cancer cells

Redox Biology

Volumn 9, Issue , 2016, Pages 210-219

  Gęgotek, Agnieszka ^a   Nikliński, Jacek ^a   Žarković, Neven ^b   Žarković, Kamelija ^c   Waeg, Georg ^d   Łuczaj, Wojciech ^a   Charkiewicz, Radosław ^a   Skrzydlewska, Elżbieta ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b RUDER BO KOVI INSTITUTE   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

^d UNIVERSITY OF GRAZ   (Austria)

Author keywords

Endocannabinoid system; Lung adenocarcinoma; Lung squamous cell carcinoma; Nrf2; Reactive aldehydes

Indexed keywords

2 ARACHIDONYLGLYCERIOL; 4 HYDROXYNONENAL; 4 OXONONENAL; 7 METHYLGUANINE; 8 HYDROXYDEOXYGUANOSINE; AGENTS AFFECTING LIPID METABOLISM; ALDEHYDE; ANANDAMIDE; ARACHIDONIC ACID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CATALASE; DOCOSAHEXAENOIC ACID; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; GLUTATHIONE PEROXIDASE; LINOLEIC ACID; LIPID MEDIATOR; MALONALDEHYDE; TRANSCRIPTION FACTOR NRF2; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; UNCLASSIFIED DRUG; ANTIOXIDANT; BIOLOGICAL MARKER;

ANTIOXIDANT ASSAY; ARTICLE; CONTROLLED STUDY; DNA MODIFICATION; HUMAN; HUMAN CELL; INFLAMMATION; LIPID PEROXIDATION; LUNG ADENOCARCINOMA; LUNG CANCER; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SQUAMOUS CELL LUNG CARCINOMA; STROMA CELL; AGED; ANTIOXIDANT RESPONSIVE ELEMENT; DNA DAMAGE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LIPID METABOLISM; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AGED; ANTIOXIDANT RESPONSE ELEMENTS; ANTIOXIDANTS; BIOMARKERS; CATALASE; CELL LINE, TUMOR; DNA DAMAGE; ENDOCANNABINOIDS; FEMALE; GENE EXPRESSION REGULATION; GLUTATHIONE PEROXIDASE; HUMANS; LIPID METABOLISM; LIPID PEROXIDATION; LUNG NEOPLASMS; MALE; MALONDIALDEHYDE; MIDDLE AGED; NF-E2-RELATED FACTOR 2; OXIDATION-REDUCTION; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 84983499585     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2016.08.010     Document Type: Article

References (89)

1. [1] Zer, A., Leighl, N., Promising targets and current clinical trials in metastatic non-squamous NSCLC. Front Oncol., 4, 2014, 329.
2. [2] Valavanidis, A., Vlachogianni, T., Fiotakis, K., Loridas, S., Pulmonary oxidative stress, inflammation and cancer: respirable particulate matter, fibrous dusts and ozone as major causes of lung carcinogenesis through reactive oxygen species mechanisms. Int J. Environ. Res. Public Health 10 (2013), 3886–3907.
3. [3] Milkovic, L., Cipak Gasparovic, A., Zarkovic, N., Overview on major lipid peroxidation bioactive factor 4-hydroxynonenal as pluripotent growth-regulating factor. Free Radic. Res 49 (2014), 850–860.
4. [4] Kansanen, E., Kuosmanen, S.M., Leinonen, H., Levonen, A.L., The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol. 1 (2013), 45–49.
5. [5] Kwak, M.K., Wakabayashi, N., Itoh, K., Motohashi, H., Yamamoto, M., Kensler, T.W., Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway Identification of novel gene clusters for cell survival. J. Biol. Chem 278 (2003), 8135–8145.
6. [6] Homma, S., Ishii, Y., Morishima, Y., Yamadori, T., Matsuno, Y., Haraguchi, N., et al. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin. Cancer Res. 15 (2009), 3423–3432.
7. [7] Gottesman, M.M., Fojo, T., Bates, S.E., Multidrug resistance in cancer: role of ATP–dependent transporters. Nat. Rev. Cancer 2 (2002), 48–58.
8. [8] Li, Q.K., Singh, A., Biswal, S., Askin, F., Gabrielson, E., KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma. J. Hum. Genet. 56 (2011), 230–234.
9. [9] Hu, Y., Ju, Y., Lin, D., Wang, Z., Huang, Y., Zhang, S., et al. Mutation of the Nrf2 gene in non-small cell lung cancer. Mol. Biol. Rep. 39 (2012), 4743–4747.
10. [10] Shibata, T., Ohta, T., Tong, K.I., Kokubu, A., Odogawa, R., Tsuta, K., et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl. Acad. Sci. 105 (2008), 13568–13573.
11. [11] Padmanabhan, B., Tong, K.I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol. Cell 21 (2006), 689–700.
12. [12] Mahaffey, C.M., Zhang, H., Rinna, A., Holland, W., Mack, P.C., Forman, H.J., Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma. Free Radic. Biol. Med. 46 (2009), 1650–1657.
13. [13] Barrera, G., Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol., 2012, 2012, 137289, 10.5402/2012/137289.
14. [14] Ravi, J., Sneh, A., Shilo, K., Nasser, M.W., Ganju, R.K., FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway. Oncotarget 5 (2014), 2475–2486.
15. [15] Hermanson, D.J., Marnett, L.J., Cannabinoids endocannabinoids, and cancer. Cancer Metastas-. Rev. 30 (2011), 599–612.
16. [16] Velasco, G., Sánchez, C., Guzmán, M., Towards the use of cannabinoids as antitumour agents. Nat. Rev. Cancer 12 (2012), 436–444.
17. [17] Blázquez, C., Carracedo, A., Barrado, L., Real, P.J., Fernández-Luna, J.L., Velasco, G., et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 20 (2006), 2633–2635.
18. [18] Freimuth, N., Ramer, R., Hinz, B., Antitumorigenic effects of cannabinoids beyond apoptosis. J. Pharm. Exp. Ther. 332 (2010), 336–344.
19. [19] Salazar, M., Carracedo, A., Salanueva, Í.J., Hernández-Tiedra, S., Lorente, M., Egia, A., et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J. Clin. Invest 119 (2009), 1359–1372.
20. [20] Haustein, M., Ramer, R., Linnebacher, M., Manda, K., Hinz, B., Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1. Biochem. Pharm. 92 (2014), 312–325.
21. [21] Ramer, R., Bublitz, K., Freimuth, N., Merkord, J., Rohde, H., Haustein, M., et al. Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J. 26 (2012), 1535–1548.
22. [22] Li, H., Wood, J.T., Whitten, K.M., Vadivel, S.K., Seng, S., Makriyannis, A., Avraham, H.K., Inhibition of fatty acid amide hydrolase activates Nrf2 signalling and induces heme oxygenase 1 transcription in breast cancer cells. Br. J. Pharm. 170 (2013), 489–505.
23. [23] Paglia, D.E., Valentine, W.N., Studies on the quantitative and qualitative characterization of erytrocyte glutathione peroxidase. J. Lab. Clin. Med 70 (1967), 158–169.
24. [24] Aebi, H., Catalase in vitro. Meth. Enzym. 105 (1984), 121–126.
25. [25] Maeso, N., Garcia-Martinez, D., Ruperez, F.J., Cifuentes, A., Barbas, C., Capillary electrophoresis of glutathione to monitor oxidative stress and response to antioxidant treatments in an animal model. J. Chromatogr. B 822 (2005), 61–69.
26. [26] Eissa, S., Seada, L.S., Quantitation of bcl-2 protein in bladder cancer tissue by enzyme immunoassay: comparison with Western blot and immunohistochemistry. Clin. Chem 44 (1998), 1423–1429.
27. [27] Bradford, M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976), 248–254.
28. [28] Dizdaroglu, M., Jaruga, P., Rodriguez, H., Measurement of 8-hydroxy-2′-deoxyguanosine in DNA by high-performance liquid chromatography-mass spectrometry: comparison with measurement by gas chromatography-mass spectrometry. Nucleic Acids Res. 29 (2001), 3–12.
29. [29] Chao, M.R., Wang, C.J., Yen, C.C., Yang, H.H., Lu, Y.C., Chang, L.W., et al. Simultaneous determination of N7-alkylguanines in DNA by isotope-dilution LC-tandem MS coupled with automated solid-phase extraction and its application to a small fish model. Biochem. J. 402 (2007), 483–490.
30. [30] Christie, W.W., Preparation of ester derivatives of fatty acids for chromatographic analysis. Christie, W.W., (eds.) Advances in Lipid Methodology – Two, 1993, Oily Press, Dundee, 69–111.
31. [31] Luo, X.P., Yazdanpanah, M., Bhooi, N., Lehotay, D.C., Determination of aldehydes and other lipid peroxidation products in biological samples by gas chromatography-mass spectrometry. Anal. Biochem. 228 (1995), 294–298.
32. [32] Weber, D., Milkovic, L., Bennett, S.J., Griffiths, H.R., Zarkovic, N., Grune, T., Measurement of HNE-protein adducts in human plasma and serum by ELISA—Comparison of two primary antibodies. Redox Biol. 1 (2013), 226–233.
33. [33] Borovic, S., Rabuzin, F., Waeg, G., Zarkovic, N., Enzyme-linked immunosorbent assay for 4-hydroxynonenal–histidine conjugates. Free Radic. Res 40 (2006), 809–820.
34. [34] Zarkovic, K., Juric, G., Waeg, G., Kolenc, D., Zarkovic, N., Immunohistochemical appearance of HNE-protein conjugates in human astrocytomas. Biofactors 24 (2005), 33–40.
35. [35] Lam, P.M., Marczylo, T.H., El-Talatini, M., Finney, M., Nallendran, V., Taylor, A.H., et al. Ultra-performance liquid chromatography tandem mass spectrometry method for the measurement of anandamide in human plasma. Anal. Biochem. 380 (2008), 195–201.
36. [36] Ulloa, N.M., Deutsch, D.G., Assessment of a spectrophotometric assay for monoacylglycerol lipase activity. AAPS J. 12 (2010), 197–201.
37. [37] Siegmund, S.V., Seki, E., Osawa, Y., Uchinami, H., Cravatt, B.F., Schwabe, R.F., Fatty Acid Amide Hydrolase Determines Anandamideinduced Cell Death in the Liver. J. Biol. Chem. 281 (2006), 10431–10438.
38. [38] Fortunati, N., Manti, R., Birocco, N., Pugliese, M., Brignardello, E., Ciuffreda, L., et al. Pro-inflammatory cytokines and oxidative stress/antioxidant parameters characterize the bio-humoral profile of early cachexia in lung cancer patients. Oncol. Rep., 18, 2007 1521–17.
39. [39] Esme, H., Cemek, M., Sezer, M., Saglam, H., Demir, A., Melek, H., et al. High levels of oxidative stress in patients with advanced lung cancer. Respirology 13 (2008), 112–116.
40. [40] Kaynar, H., Meral, M., Turhan, H., Keles, M., Celik, G., et al. Glutathione peroxidase, glutathione-S-transferase, catalase, xanthine oxidase, Cu-Zn superoxide dismutase activities, total glutathione, nitric oxide, and malondialdehyde levels in erythrocytes of patients with small cell and non-small cell lung cancer. Cancer Lett. 227 (2005), 133–139.
41. [41] Sun, S., Schiller, J.H., Gazdar, A.F., Lung cancer in never smokers—a different disease. Nat. Rev. Cancer 7 (2007), 778–790.
42. [42] Crawford, E.L., Khuder, S.A., Durham, S.J., Frampton, M., Utell, M., Thilly, W.G., et al. Normal bronchial epithelial cell expression of glutathione transferase P1, glutathione transferase M3, and glutathione peroxidase is low in subjects with bronchogenic carcinoma. Cancer Res. 60 (2000), 1609–1618.
43. [43] Lee, C.H., Lee, K.Y., Choe, K.H., Hong, Y.C., Noh, S.I., Eom, S.Y., et al. Effects of oxidative DNA damage and genetic polymorphism of the glutathione peroxidase 1 (GPX1) and 8-oxoguanine glycosylase 1 (hOGG1) on lung cancer. J. Prev. Med. Public Health 39 (2006), 130–134.
44. [44] Zieba, M., Suwalski, M., Kwiatkowska, S., Piasecka, G., Grzelewska-Rzymowska, G., Stolarek, R., et al. Comparison of hydrogen peroxide generation and the content of lipid peroxidation products in lung cancer tissue and pulmonary parenchyma. Respir. Med. 94 (2000), 800–805.
45. [45] Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys. Res Commun. 236 (1997), 313–322.
46. [46] Jaramillo, M.C., Zhang, D.D., The emerging role of the Nrf2–Keap1 signaling pathway in cancer. Genes Dev. 27 (2013), 2179–2191.
47. [47] Singh, A., Misra, V., Thimmulappa, R.K., Lee, H., Ames, S., Hoque, M.O., et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med., 3, 2006, e420.
48. [48] Lee, S., Lim, M.J., Kim, M.H., Yu, C.H., Yun, Y.S., Ahn, J., et al. An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses. Free Radic. Biol. Med. 53 (2012), 807–816.
49. [49] Chien, M.H., Lee, W.J., Hsieh, F.K., Li, C.F., Cheng, T.Y., Wang, M.Y., et al. Keap1-Nrf2 interaction suppresses cell motility in lung adenocarcinomas by targeting the S100P protein. Clin. Cancer Res. 21 (2015), 4719–4732.
50. [50] Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22 (2012), 66–79.
51. [51] Wang, Q., Zheng, X.L., Yang, L., Shi, F., Gao, L.B., Zhong, Y.J., et al. Reactive oxygen species-mediated apoptosis contributes to chemosensitization effect of saikosaponins on cisplatin-induced cytotoxicity in cancer cells. J. Exp. Clin. Cancer Res 29 (2010), 159–164.
52. [52] Muscarella, L.A., Parrella, P., D'Alessandro, V., la Torre, A., Barbano, R., Fontana, A., et al. Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. Epigenetics 6 (2011), 710–719.
53. [53] Kim, H.R., Kim, S., Kim, E.J., Park, J.H., Yang, S.H., Jeong, E.T., et al. Suppression of Nrf2-driven heme oxygenase-1 enhances the chemosensitivity of lung cancer A549 cells toward cisplatin. Lung Cancer 60 (2008), 47–56.
54. [54] Singh, S., Vrishni, S., Singh, B.K., Rahman, I., Kakkar, P., Nrf2-ARE stress response mechanism: a control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases. Free Radic. Res. 44 (2010), 1267–1288.
55. [55] Boulaire, J., Fotedar, A., Fotedar, R., The functions of the cdk-cyclin kinase inhibitor p21WAF1. Pathol. Biol. 48 (2000), 190–202.
56. [56] Russo, T., Zambrano, N., Esposito, F., Ammendola, R., Cimino, F., Fiscella, M., et al. A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J. Biol. Chem. 270 (1995), 29386–29391.
57. [57] Wu, L.L., Chiou, C.C., Chang, P.Y., Wu, J.T., Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin. Chim. Acta 339 (2004), 1–9.
58. [58] Ishimura, R., Tanaka, K., Komatsu, M., Dissection of the role of p62/Sqstm1 in activation of Nrf2 during xenophagy. FEBS Lett. 588 (2014), 822–828.
59. [59] Duran, A., Linares, J.F., Galvez, A.S., Wikenheiser, K., Flores, J.M., Diaz-Meco, M.T., et al. The signaling adaptor p62 is an important NF-κB mediator in tumorigenesis. Cancer Cell 13 (2008), 343–354.
60. [60] Fourquet, S., Guerois, R., Biard, D., Toledano, M.B., Activation of NRF2 by nitrosative agents and H2O2 involves KEAP1 disulfide formation. J. Biol. Chem. 285 (2010), 8463–8471.
61. [61] Wang, X.J., Sun, Z., Villeneuve, N.F., Zhang, S., Zhao, F., Li, Y., et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29 (2008), 1235–1243.
62. [62] Ishikawa, M., Numazawa, S., Yoshida, T., Redox regulation of the transcriptional repressor Bach1. Free Radic. Biol. Med. 38 (2005), 1344–1352.
63. [63] Rahman, I., van Schadewijk, A.A., Crowther, A.J., Hiemstra, P.S., Stolk, J., MacNee, W., et al. 4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 166 (2002), 490–495.
64. [64] Riahi, Y., Cohen, G., Shamni, O., Sasson, S., Signaling and cytotoxic functions of 4-hydroxyalkenals. Am. J. Physiol. Endocrinol. Metab. 299 (2010), E879–E886.
65. [65] Vistoli, G., De Maddis, D., Cipak, A., Zarkovic, N., Carini, M., Aldini, G., Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. Free Radic. Res. 47 (2013), 3–27.
66. [66] Custovic, Z., Zarkovic, K., Cindric, M., Cipak, A., Jurkovic, I., Sonicki, Z., Uchida, K., Zarkovic, N., Lipid peroxidation product acrolein as predictive biomarker of prostate carcinoma relapse after radical surgery. Free Radic. Res. 45 (2010), 497–504.
67. [67] Borovic, S., Cipak, A., Meinitzer, A., Kejla, Z., Perovic, D., Waeg, G., Zarkovic, N., Differential effect of 4-hydroxynonenal on normal and malignant mesenchimal cells. Redox Rep. 207 (2007), 50–54.
68. [68] Zarkovic, N., Zarkovic, K., Schaur, R.J., Stolc, S., Schlag, G., Redl, H., et al. 4-Hydroxynonenal as a second messenger of free radicals and growth modifying factor. Life Sci. 65 (1999), 1901–1904.
69. [69] Bauer, G., Zarkovic, N., Revealing mechanisms of selective, concentration-dependent potentials of 4-hydroxy-2-nonenal to induce apoptosis in cancer cells through inactivation of membrane-associated catalase. Free Radic. Biol. Med. 81 (2015), 128–144.
70. [70] Wuttge, D.M., Bruzelius, M., Stemme, S., T-cell recognition of lipid peroxidation products breaks tolerance to self-proteins. Immunology 98 (1999), 273–279.
71. [71] Jaganjac, M., Poljak-Blazi, M., Zarkovic, K., Schaur, R.J., Zarkovic, N., The involvement of granulocytes in spontaneous regression of Walker 256 carcinoma. Cancer Lett. 260 (2008), 180–186.
72. [72] Jaganjac, M., Poljak-Blazi, M., Zarkovic, K., Schaur, R.J., Borovic, S., Matijevic, T., et al. Elevated neutrophil elastase and acrolein-protein adducts are associated with W256 regression. Clin. Expe Immunol. 170 (2012), 178–185.
73. [73] Levonen, A.L., Landar, A., Ramachandran, A., Ceaser, E.K., Dickinson, D.A., Zanoni, G., et al. Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem. J. 378 (2004), 373–382.
74. [74] Lopachin, R.M., Gavin, T., Decaprio, A., Barber, D.S., Application of the Hard and Soft, Acids and Bases (HSAB) theory to toxicant–target interactions. Chem. Res. Toxicol. 25 (2012), 239–251.
75. [75] Brandes, N., Schmitt, S., Jakob, U., Thiol-based redox switches in eukaryotic proteins. Antioxid. Redox Signal 11 (2009), 997–1014.
76. [76] Yin, G., Wang, Y., Cen, X., Yang, M., Liang, Y., Xie, Q., Lipid peroxidation-mediated inflammation promotes cell apoptosis through activation of NF-κB pathway in rheumatoid arthritis synovial cells. Mediat. Inflamm. 2015 (2015), 1–10.
77. [77] Chaudhary, P., Sharma, R., Sharma, A., Vatsyayan, R., Yadav, S., Singhal, S.S., et al. Mechanisms of 4-hydroxy-2-nonenal induced pro- and anti-apoptotic signaling. Biochemistry 49 (2010), 6263–6275.
78. [78] Zarkovic, N., Cipak, A., Jaganjac, M., Borovic, S., Zarkovic, K., Pathophysiological relevance of aldehydic protein modifications. J. Proteom. 92 (2013), 239–247.
79. [79] Gönenç, A., Ozkan, Y., Torun, M., Simşek, B., Plasma malondialdehyde (MDA) levels in breast and lung cancer patients. J. Clin. Pharm. Ther. 26 (2001), 141–144.
80. [80] Panikashvili, D., Mechoulam, R., Beni, S.M., Alexandrovich, A., Shohami, E., CB1 cannabinoid receptors are involved in neuroprotection via NF-κB inhibition. J. Cereb. Blood Flow. Metab. 25 (2005), 477–484.
81. [81] Pacher, P., Batkai, S., Kunos, G., The endocannabinoid system as an emerging target of pharmacotherapy. Pharm. Rev. 58 (2006), 389–462.
82. [82] Alpini, G., DeMorrow, S., Changes in the endocannabinoid system may give insight into new and effective treatments for cancer. Vitam. Horm. 81 (2009), 469–485.
83. [83] Patsos, H.A., Greenhough, A., Hicks, D.J., Al Kharusi, M., Collard, T.J., Lane, J.D., et al. The endogenous cannabinoid, anandamide, induces COX-2-dependent cell death in apoptosis-resistant colon cancer cells. Int J. Oncol. 37 (2010), 187–193.
84. [84] Ravi, J., Sneh, A., Shilo, K., Nasser, M.W., Ganju, R.K., FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway. Oncotarget 5 (2014), 2475–2486.
85. [85] Pisanti, S., Bifulco, M., Endocannabinoid system modulation in cancer biology and therapy. Pharm. Res. 60 (2009), 107–116.
86. [86] Pisanti, S., Picardi, P., D'Alessandro, A., Laezza, C., Bifulco, M., The endocannabinoid signaling system in cancer. Trends Pharmacol. Sci. 34 (2013), 273–282.
87. [87] Preet, A., Ganju, R.K., Groopman, J.E., Δ9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 27 (2008), 339–346.
88. [88] Felder, C.C., Joyce, K.E., Briley, E.M., Mansouri, J., Mackie, K., Blond, O., et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharm. 48 (1995), 443–450.
89. [89] Preet, A., Qamri, Z., Nasser, M.W., Prasad, A., Shilo, K., Zou, X., et al. Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non–small cell lung cancer growth and metastasis. Cancer Prev. Res. 4 (2011), 65–75.